Previous 10 | Next 10 |
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (N...
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20 th Annual Global H...
Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "...
Summary Neurocrine is acquiring beaten-down Diurnal Group for $57M, primarily to accelerate its ex-U.S. business development. Diurnal has a pipeline of hormone-based therapeutics, including Efmody (commercialized in Europe), but the pipeline is likely secondary to the clinical/com...
The shares of U.K.-based biotech Diurnal rose in London in the morning hours Tuesday after the company announced a deal to be acquired by San Diego, California-based Neurocrine Biosciences ( NASDAQ: NBIX ) for nearly $57M in cash. Per the terms, neurology-focused NBIX will...
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts. ...
Improving VBR pick performance since late July is discussed. 5 new buy signals are highlighted. A super-bullish technical and fundamental setup for Canadian Solar is analyzed in more detail. During the last few weeks, I have been able to find some decent winners for Seek...
Neurocrine Biosciences ( NASDAQ: NBIX ) stock rose ~8% on Aug. 5 after the company's Q2 revenue beat estimates. Total revenues grew 31% Y/Y to $378.2M, while product sales increased 32% Y/Y to $352M. Tardive dyskinesia (TD) therapy Ingrezza sales amounted t...
Sosei Group ( OTCPK:SOLTF ) is getting $30M as a milestone payment from Neurocrine Biosciences ( NASDAQ: NBIX ) as NBI-1117568 was cleared by the U.S. Food and Drug Administration (FDA) for a phase 2 trial to treat schizophrenia. Neurocrine's investigatio...
Image source: The Motley Fool. Neurocrine Biosciences (NASDAQ: NBIX) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $170.00 for NBIX on 2024-07-12 08:10:00. The adjusted price target was set to $170.00. At the time of the announcement, NBIX was trading at $146.5. The overall price target consensus is at $...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...